Protection against lipopolysaccharide-induced death by fluoroquinolones

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 3169-3173

  Khan, A A ^a   Slifer, T R ^a   Araujo, F G ^a   Suzuki, Y ^a   Remington, J S ^a  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CIPROFLOXACIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOSUFLOXACIN; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEATH; FEMALE; IMMUNOMODULATION; LETHAL DOSE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CYTOKINES; DEATH; DRUG INTERACTIONS; FLUOROQUINOLONES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MONOCYTES; NAPHTHYRIDINES; PROTECTIVE AGENTS; SHOCK, SEPTIC;

EID: 0033735177     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.3169-3173.2000     Document Type: Article

References (22)

1. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
2. The role of platelet activating factor and its antagonists in shock, gram negative sepsis and multiple organ failure Surg
3. Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide-stimulated human monocytes to produce IL-1 IL-6 and tumour necrosis factor-alpha
4. Tumor necrosis, cachexia, shock, and inflammation: A common mediator
5. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, clinical trial
6. A controlled trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock
7. Interleukin 1-induced pathophysiology: Induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention
8. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
9. Sepsis and serum cytokine concentrations
10. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial
11. Interleukin-1
12. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome
13. Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity
14. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis
15. Effect of trovafloxacin on production of cytokines by human monocytes
16. Pathobiology of lipopolysaccharide
17. Pathogenetic mechanisms of septic shock
18. Acute in vivo effects of human recombinant tumor necrosis factor
19. Immunological aspects of new quinolones
20. Anti-inflammatory cytokine responses during sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin-1 receptor type II, IL-10, and IL-13
21. Cytokines in septic shock
22. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin